{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:55:59Z","timestamp":1793141759654,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.biomaterials.2026.124099","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T16:03:44Z","timestamp":1772121824000},"page":"124099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["\u03b2-Selenoester-Crosslinked nanocapsules potentiate immunotherapy by imposing divergent fates in cancer cells and macrophages"],"prefix":"10.1016","volume":"331","author":[{"given":"Banruo","family":"Xianyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7530-7264","authenticated-orcid":false,"given":"Huaping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3719-1459","authenticated-orcid":false,"given":"Tianyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2026.124099_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.02.039","article-title":"Advances in cancer immunotherapies","volume":"186","author":"Dagher","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.biomaterials.2026.124099_bib3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biomaterials.2026.124099_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41571-022-00718-x","article-title":"At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC","volume":"20","author":"Otano","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib5","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","article-title":"Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC","volume":"16","author":"Camidge","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib6","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for Non\u2013small-cell lung cancer","volume":"40","author":"Reck","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib7","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdz141","article-title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","volume":"30","author":"Hastings","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib8","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-Mutant, PD-L1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","article-title":"Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial","volume":"29","author":"Cascone","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.biomaterials.2026.124099_bib10","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.20.03579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic Non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%: randomized, double-blind phase III KEYNOTE-598 study","volume":"39","author":"Boyer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12943-019-1062-7","article-title":"Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations","volume":"18","author":"Lin","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124099_bib12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41467-019-14273-0","article-title":"Comprehensive T cell repertoire characterization of non-small cell lung cancer","volume":"11","author":"Reuben","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124099_bib13","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non\u2013small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2026.124099_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e20517","article-title":"Investigation of immune microenvironment in EGFR mutant NSCLC","volume":"39","author":"Hu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.123028","article-title":"Emerging nanomedicines for macrophage-mediated cancer therapy","volume":"316","author":"Shi","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2026.124099_bib16","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.biomaterials.2026.124099_bib17","article-title":"CD47 promotes tumor invasion and metastasis in non-small cell lung cancer","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biomaterials.2026.124099_bib18","article-title":"Engineered cellular vesicles displaying glycosylated nanobodies for cancer immunotherapy","volume":"63","author":"Wu","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biomaterials.2026.124099_bib19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma","volume":"42","author":"Chao","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.biomaterials.2026.124099_bib20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting CD47 for cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib21","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jtho.2024.03.019","article-title":"EGFR oncogenic mutations in NSCLC impair macrophage phagocytosis and mediate innate immune evasion through Up-Regulation of CD47","volume":"19","author":"Hu","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib22","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.3389\/fimmu.2019.03135","article-title":"Enhanced expression of CD47 is associated with off-target resistance to tyrosine kinase inhibitor gefitinib in NSCLC","volume":"10","author":"Nigro","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib23","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.7150\/thno.48662","article-title":"Nanomedicine of tyrosine kinase inhibitors","volume":"11","author":"Smidova","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.biomaterials.2026.124099_bib24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/cac2.12139","article-title":"Diverse effects of chemotherapeutic agents on immune cell function and implications in immunochemotherapy","volume":"41","author":"Glorieux","year":"2021","journal-title":"Cancer Commun."},{"key":"10.1016\/j.biomaterials.2026.124099_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009165","article-title":"Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect","volume":"12","author":"Lu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biomaterials.2026.124099_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s40820-020-00482-6","article-title":"A review on nano-based drug delivery system for cancer chemoimmunotherapy","volume":"12","author":"Mu","year":"2020","journal-title":"Nano-Micro Lett."},{"key":"10.1016\/j.biomaterials.2026.124099_bib27","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)61452-9","article-title":"Selenium and human health","volume":"379","author":"Rayman","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.biomaterials.2026.124099_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1152\/physrev.00039.2013","article-title":"Gladyshev. Selenoproteins: molecular pathways and physiological roles","volume":"94","author":"Labunskyy","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biomaterials.2026.124099_bib29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2958.1991.tb00722.x","article-title":"Selenocysteine: the 21st amino acid","volume":"5","author":"B\u00f6ck","year":"1991","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib30","first-page":"182","article-title":"Selenium-Derived bioactive enablers for advanced therapies: from molecular redox modulation to broad-spectrum disease applications","volume":"57","author":"Ding","year":"2026","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.biomaterials.2026.124099_bib31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1021\/ja908124g","article-title":"Dual redox responsive assemblies formed from diselenide block copolymers","volume":"132","author":"Ma","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biomaterials.2026.124099_bib32","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1002\/anie.201914453","article-title":"Diselenide\u2013pemetrexed assemblies for combined cancer Immuno-, Radio-, and chemotherapies","volume":"59","author":"Li","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biomaterials.2026.124099_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120054","article-title":"Anti-Recurrence\/Metastasis and chemosensitization therapy with thioredoxin reductase-interfering drug delivery system","volume":"249","author":"Yang","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2026.124099_bib34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41580-020-0230-3","article-title":"Reactive oxygen species (ROS) as pleiotropic physiological signalling agents","volume":"21","author":"Sies","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202403880","article-title":"Quantitative factors introduced in the feasibility analysis of reactive oxygen species (ROS)-sensitive triggers","volume":"63","author":"Kondengadan","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biomaterials.2026.124099_bib36","doi-asserted-by":"crossref","first-page":"21546","DOI":"10.1002\/anie.202005612","article-title":"External-radiation-induced local hydroxylation enables remote release of functional molecules in tumors","volume":"59","author":"Fu","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.biomaterials.2026.124099_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121856","article-title":"Activating cGAS-STING pathway with ROS-responsive nanoparticles delivering a hybrid prodrug for enhanced chemo-immunotherapy","volume":"290","author":"Cao","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2026.124099_bib38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.31635\/ccschem.020.202000140","article-title":"A ROS-responsive aspirin polymeric prodrug for modulation of tumor microenvironment and cancer immunotherapy","volume":"2","author":"Ma","year":"2020","journal-title":"CCS Chem."},{"key":"10.1016\/j.biomaterials.2026.124099_bib39","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.4049\/jimmunol.1100610","article-title":"Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94\/NKG2A-Positive NK cells","volume":"187","author":"Enqvist","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124099_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202108167","article-title":"Selenopeptide nanomedicine activates natural killer cells for enhanced tumor chemoimmunotherapy","volume":"34","author":"Wei","year":"2022","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2026.124099_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121321","article-title":"Selenium-containing nanoparticles synergistically enhance Pemetrexed&NK cell-based chemoimmunotherapy","volume":"280","author":"Pan","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2026.124099_bib42","article-title":"Translational selenium nanoparticles promotes clinical non-small-cell lung cancer chemotherapy via activating selenoprotein-driven immune manipulation","volume":"37","author":"Yu","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2026.124099_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119514","article-title":"Selenoxide elimination manipulate the oxidative stress to improve the antitumor efficacy","volume":"225","author":"Sun","year":"2019","journal-title":"Biomaterials"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226001237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226001237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:18:45Z","timestamp":1779337125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961226001237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":43,"alternative-id":["S0142961226001237"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124099","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u03b2-Selenoester-Crosslinked nanocapsules potentiate immunotherapy by imposing divergent fates in cancer cells and macrophages","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124099"}}